nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—HTR1F—trigeminal nerve—peripheral nervous system neoplasm	0.118	0.283	CbGeAlD
Methylergometrine—HTR2A—phrenic nerve—peripheral nervous system neoplasm	0.0639	0.152	CbGeAlD
Methylergometrine—HTR1F—ganglion—peripheral nervous system neoplasm	0.0427	0.102	CbGeAlD
Methylergometrine—HTR2A—trigeminal nerve—peripheral nervous system neoplasm	0.0233	0.0558	CbGeAlD
Methylergometrine—DRD1—nerve—peripheral nervous system neoplasm	0.0219	0.0522	CbGeAlD
Methylergometrine—HTR2A—vagus nerve—peripheral nervous system neoplasm	0.0218	0.0521	CbGeAlD
Methylergometrine—DRD1—ganglion—peripheral nervous system neoplasm	0.0216	0.0516	CbGeAlD
Methylergometrine—HTR2C—ganglion—peripheral nervous system neoplasm	0.0168	0.0401	CbGeAlD
Methylergometrine—HTR2A—cranial nerve—peripheral nervous system neoplasm	0.0166	0.0397	CbGeAlD
Methylergometrine—HTR2A—pons—peripheral nervous system neoplasm	0.0164	0.0393	CbGeAlD
Methylergometrine—HTR1E—brainstem—peripheral nervous system neoplasm	0.0161	0.0384	CbGeAlD
Methylergometrine—DRD1—brainstem—peripheral nervous system neoplasm	0.00939	0.0224	CbGeAlD
Methylergometrine—HTR2A—nerve—peripheral nervous system neoplasm	0.00853	0.0204	CbGeAlD
Methylergometrine—HTR2A—ganglion—peripheral nervous system neoplasm	0.00842	0.0201	CbGeAlD
Methylergometrine—HTR2C—brainstem—peripheral nervous system neoplasm	0.0073	0.0174	CbGeAlD
Methylergometrine—Nasal congestion—Isotretinoin—peripheral nervous system neoplasm	0.00718	0.0137	CcSEcCtD
Methylergometrine—Nasal congestion—Tretinoin—peripheral nervous system neoplasm	0.00718	0.0137	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Tretinoin—peripheral nervous system neoplasm	0.00667	0.0128	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Isotretinoin—peripheral nervous system neoplasm	0.00667	0.0128	CcSEcCtD
Methylergometrine—Sweating increased—Isotretinoin—peripheral nervous system neoplasm	0.0055	0.0105	CcSEcCtD
Methylergometrine—Sweating increased—Tretinoin—peripheral nervous system neoplasm	0.0055	0.0105	CcSEcCtD
Methylergometrine—Nasal congestion—Alitretinoin—peripheral nervous system neoplasm	0.00544	0.0104	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Alitretinoin—peripheral nervous system neoplasm	0.00506	0.00967	CcSEcCtD
Methylergometrine—Haematuria—Tretinoin—peripheral nervous system neoplasm	0.0048	0.00919	CcSEcCtD
Methylergometrine—Haematuria—Isotretinoin—peripheral nervous system neoplasm	0.0048	0.00919	CcSEcCtD
Methylergometrine—Ergonovine—ABCB1—peripheral nervous system neoplasm	0.00471	0.475	CrCbGaD
Methylergometrine—Nasal congestion—Cisplatin—peripheral nervous system neoplasm	0.00463	0.00886	CcSEcCtD
Methylergometrine—Hallucination—Tretinoin—peripheral nervous system neoplasm	0.0045	0.00861	CcSEcCtD
Methylergometrine—Hallucination—Isotretinoin—peripheral nervous system neoplasm	0.0045	0.00861	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Cisplatin—peripheral nervous system neoplasm	0.00431	0.00824	CcSEcCtD
Methylergometrine—Tinnitus—Isotretinoin—peripheral nervous system neoplasm	0.00422	0.00806	CcSEcCtD
Methylergometrine—Tinnitus—Tretinoin—peripheral nervous system neoplasm	0.00422	0.00806	CcSEcCtD
Methylergometrine—Sweating increased—Alitretinoin—peripheral nervous system neoplasm	0.00417	0.00798	CcSEcCtD
Methylergometrine—Muscle spasms—Topotecan—peripheral nervous system neoplasm	0.00382	0.0073	CcSEcCtD
Methylergometrine—HTR2A—brainstem—peripheral nervous system neoplasm	0.00366	0.00874	CbGeAlD
Methylergometrine—Haematuria—Alitretinoin—peripheral nervous system neoplasm	0.00364	0.00696	CcSEcCtD
Methylergometrine—Sweating increased—Cisplatin—peripheral nervous system neoplasm	0.00355	0.0068	CcSEcCtD
Methylergometrine—Palpitations—Tretinoin—peripheral nervous system neoplasm	0.00348	0.00665	CcSEcCtD
Methylergometrine—Palpitations—Isotretinoin—peripheral nervous system neoplasm	0.00348	0.00665	CcSEcCtD
Methylergometrine—Convulsion—Tretinoin—peripheral nervous system neoplasm	0.00341	0.00652	CcSEcCtD
Methylergometrine—Convulsion—Isotretinoin—peripheral nervous system neoplasm	0.00341	0.00652	CcSEcCtD
Methylergometrine—Hallucination—Alitretinoin—peripheral nervous system neoplasm	0.00341	0.00652	CcSEcCtD
Methylergometrine—Hypertension—Tretinoin—peripheral nervous system neoplasm	0.0034	0.0065	CcSEcCtD
Methylergometrine—Hypertension—Isotretinoin—peripheral nervous system neoplasm	0.0034	0.0065	CcSEcCtD
Methylergometrine—Chest pain—Topotecan—peripheral nervous system neoplasm	0.00338	0.00646	CcSEcCtD
Methylergometrine—Convulsion—Melphalan—peripheral nervous system neoplasm	0.00337	0.00644	CcSEcCtD
Methylergometrine—Chest pain—Isotretinoin—peripheral nervous system neoplasm	0.00335	0.00641	CcSEcCtD
Methylergometrine—Chest pain—Tretinoin—peripheral nervous system neoplasm	0.00335	0.00641	CcSEcCtD
Methylergometrine—Chest pain—Melphalan—peripheral nervous system neoplasm	0.00331	0.00633	CcSEcCtD
Methylergometrine—Hallucination—Vincristine—peripheral nervous system neoplasm	0.00329	0.00628	CcSEcCtD
Methylergometrine—Sweating increased—Etoposide—peripheral nervous system neoplasm	0.00326	0.00623	CcSEcCtD
Methylergometrine—Anaphylactic shock—Topotecan—peripheral nervous system neoplasm	0.00324	0.00619	CcSEcCtD
Methylergometrine—Anaphylactic shock—Tretinoin—peripheral nervous system neoplasm	0.00321	0.00615	CcSEcCtD
Methylergometrine—Anaphylactic shock—Isotretinoin—peripheral nervous system neoplasm	0.00321	0.00615	CcSEcCtD
Methylergometrine—Tinnitus—Alitretinoin—peripheral nervous system neoplasm	0.0032	0.00611	CcSEcCtD
Methylergometrine—Nervous system disorder—Topotecan—peripheral nervous system neoplasm	0.00318	0.00607	CcSEcCtD
Methylergometrine—Anaphylactic shock—Melphalan—peripheral nervous system neoplasm	0.00317	0.00607	CcSEcCtD
Methylergometrine—Nervous system disorder—Isotretinoin—peripheral nervous system neoplasm	0.00315	0.00603	CcSEcCtD
Methylergometrine—Nervous system disorder—Tretinoin—peripheral nervous system neoplasm	0.00315	0.00603	CcSEcCtD
Methylergometrine—Tachycardia—Tretinoin—peripheral nervous system neoplasm	0.00314	0.006	CcSEcCtD
Methylergometrine—Tachycardia—Isotretinoin—peripheral nervous system neoplasm	0.00314	0.006	CcSEcCtD
Methylergometrine—Hyperhidrosis—Topotecan—peripheral nervous system neoplasm	0.00313	0.00599	CcSEcCtD
Methylergometrine—Hyperhidrosis—Isotretinoin—peripheral nervous system neoplasm	0.00311	0.00594	CcSEcCtD
Methylergometrine—Hyperhidrosis—Tretinoin—peripheral nervous system neoplasm	0.00311	0.00594	CcSEcCtD
Methylergometrine—Tachycardia—Melphalan—peripheral nervous system neoplasm	0.00309	0.00592	CcSEcCtD
Methylergometrine—Atrioventricular block—Epirubicin—peripheral nervous system neoplasm	0.00308	0.00589	CcSEcCtD
Methylergometrine—Cardiac disorder—Vincristine—peripheral nervous system neoplasm	0.00306	0.00586	CcSEcCtD
Methylergometrine—Hypotension—Tretinoin—peripheral nervous system neoplasm	0.003	0.00574	CcSEcCtD
Methylergometrine—Hypotension—Isotretinoin—peripheral nervous system neoplasm	0.003	0.00574	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Epirubicin—peripheral nervous system neoplasm	0.00299	0.00571	CcSEcCtD
Methylergometrine—Bradycardia—Cisplatin—peripheral nervous system neoplasm	0.00297	0.00569	CcSEcCtD
Methylergometrine—Hypotension—Melphalan—peripheral nervous system neoplasm	0.00296	0.00567	CcSEcCtD
Methylergometrine—Paraesthesia—Topotecan—peripheral nervous system neoplasm	0.00291	0.00556	CcSEcCtD
Methylergometrine—Dyspnoea—Topotecan—peripheral nervous system neoplasm	0.00289	0.00552	CcSEcCtD
Methylergometrine—Paraesthesia—Tretinoin—peripheral nervous system neoplasm	0.00288	0.00552	CcSEcCtD
Methylergometrine—Paraesthesia—Isotretinoin—peripheral nervous system neoplasm	0.00288	0.00552	CcSEcCtD
Methylergometrine—Dyspnoea—Tretinoin—peripheral nervous system neoplasm	0.00286	0.00548	CcSEcCtD
Methylergometrine—Dyspnoea—Isotretinoin—peripheral nervous system neoplasm	0.00286	0.00548	CcSEcCtD
Methylergometrine—Atrioventricular block—Doxorubicin—peripheral nervous system neoplasm	0.00285	0.00545	CcSEcCtD
Methylergometrine—Paraesthesia—Melphalan—peripheral nervous system neoplasm	0.00285	0.00545	CcSEcCtD
Methylergometrine—Dyspnoea—Melphalan—peripheral nervous system neoplasm	0.00283	0.00541	CcSEcCtD
Methylergometrine—Ventricular tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.00276	0.00529	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Epirubicin—peripheral nervous system neoplasm	0.00274	0.00525	CcSEcCtD
Methylergometrine—Tinnitus—Cisplatin—peripheral nervous system neoplasm	0.00272	0.00521	CcSEcCtD
Methylergometrine—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.00271	0.00518	CcSEcCtD
Methylergometrine—Ergotamine—ABCB1—peripheral nervous system neoplasm	0.00265	0.267	CrCbGaD
Methylergometrine—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.00265	0.00507	CcSEcCtD
Methylergometrine—Palpitations—Alitretinoin—peripheral nervous system neoplasm	0.00264	0.00504	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00263	0.00503	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00263	0.00503	CcSEcCtD
Methylergometrine—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.00258	0.00494	CcSEcCtD
Methylergometrine—Hypertension—Alitretinoin—peripheral nervous system neoplasm	0.00258	0.00493	CcSEcCtD
Methylergometrine—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.00256	0.0049	CcSEcCtD
Methylergometrine—Bromocriptine—ABCB1—peripheral nervous system neoplasm	0.00256	0.258	CrCbGaD
Methylergometrine—Chest pain—Alitretinoin—peripheral nervous system neoplasm	0.00254	0.00486	CcSEcCtD
Methylergometrine—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.00254	0.00486	CcSEcCtD
Methylergometrine—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.00254	0.00486	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Doxorubicin—peripheral nervous system neoplasm	0.00254	0.00485	CcSEcCtD
Methylergometrine—Thrombophlebitis—Epirubicin—peripheral nervous system neoplasm	0.0025	0.00479	CcSEcCtD
Methylergometrine—Convulsion—Vincristine—peripheral nervous system neoplasm	0.00249	0.00476	CcSEcCtD
Methylergometrine—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.00248	0.00475	CcSEcCtD
Methylergometrine—Hypertension—Vincristine—peripheral nervous system neoplasm	0.00248	0.00475	CcSEcCtD
Methylergometrine—Muscle spasms—Cisplatin—peripheral nervous system neoplasm	0.00244	0.00467	CcSEcCtD
Methylergometrine—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.00243	0.00466	CcSEcCtD
Methylergometrine—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.00239	0.00457	CcSEcCtD
Methylergometrine—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.00238	0.00455	CcSEcCtD
Methylergometrine—Hyperhidrosis—Alitretinoin—peripheral nervous system neoplasm	0.00235	0.0045	CcSEcCtD
Methylergometrine—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.00235	0.00449	CcSEcCtD
Methylergometrine—Thrombophlebitis—Doxorubicin—peripheral nervous system neoplasm	0.00232	0.00443	CcSEcCtD
Methylergometrine—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.0023	0.0044	CcSEcCtD
Methylergometrine—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.00228	0.00435	CcSEcCtD
Methylergometrine—Hyperhidrosis—Vincristine—peripheral nervous system neoplasm	0.00227	0.00434	CcSEcCtD
Methylergometrine—Muscle spasms—Etoposide—peripheral nervous system neoplasm	0.00224	0.00428	CcSEcCtD
Methylergometrine—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00222	0.00424	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Epirubicin—peripheral nervous system neoplasm	0.00221	0.00423	CcSEcCtD
Methylergometrine—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.0022	0.00421	CcSEcCtD
Methylergometrine—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.0022	0.0042	CcSEcCtD
Methylergometrine—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.0022	0.0042	CcSEcCtD
Methylergometrine—Hypotension—Vincristine—peripheral nervous system neoplasm	0.00219	0.00419	CcSEcCtD
Methylergometrine—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.00219	0.00418	CcSEcCtD
Methylergometrine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.00217	0.00415	CcSEcCtD
Methylergometrine—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00217	0.00415	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00215	0.00411	CcSEcCtD
Methylergometrine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.00214	0.0041	CcSEcCtD
Methylergometrine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00212	0.00406	CcSEcCtD
Methylergometrine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00212	0.00406	CcSEcCtD
Methylergometrine—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.00211	0.00403	CcSEcCtD
Methylergometrine—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.00208	0.00397	CcSEcCtD
Methylergometrine—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.00207	0.00397	CcSEcCtD
Methylergometrine—Vomiting—Topotecan—peripheral nervous system neoplasm	0.00206	0.00394	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.00205	0.00391	CcSEcCtD
Methylergometrine—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00204	0.00391	CcSEcCtD
Methylergometrine—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00204	0.00391	CcSEcCtD
Methylergometrine—Rash—Topotecan—peripheral nervous system neoplasm	0.00204	0.00391	CcSEcCtD
Methylergometrine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00204	0.0039	CcSEcCtD
Methylergometrine—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.00203	0.00389	CcSEcCtD
Methylergometrine—Headache—Topotecan—peripheral nervous system neoplasm	0.00203	0.00388	CcSEcCtD
Methylergometrine—Rash—Tretinoin—peripheral nervous system neoplasm	0.00203	0.00387	CcSEcCtD
Methylergometrine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00203	0.00387	CcSEcCtD
Methylergometrine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.00202	0.00387	CcSEcCtD
Methylergometrine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.00202	0.00387	CcSEcCtD
Methylergometrine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.00202	0.00387	CcSEcCtD
Methylergometrine—Convulsion—Etoposide—peripheral nervous system neoplasm	0.00202	0.00386	CcSEcCtD
Methylergometrine—Vomiting—Melphalan—peripheral nervous system neoplasm	0.00202	0.00386	CcSEcCtD
Methylergometrine—Headache—Tretinoin—peripheral nervous system neoplasm	0.00201	0.00385	CcSEcCtD
Methylergometrine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00201	0.00385	CcSEcCtD
Methylergometrine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.00201	0.00385	CcSEcCtD
Methylergometrine—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.00201	0.00384	CcSEcCtD
Methylergometrine—Rash—Melphalan—peripheral nervous system neoplasm	0.002	0.00382	CcSEcCtD
Methylergometrine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.002	0.00382	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00199	0.00381	CcSEcCtD
Methylergometrine—Chest pain—Etoposide—peripheral nervous system neoplasm	0.00198	0.00379	CcSEcCtD
Methylergometrine—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00194	0.00371	CcSEcCtD
Methylergometrine—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.00192	0.00368	CcSEcCtD
Methylergometrine—Nausea—Topotecan—peripheral nervous system neoplasm	0.00192	0.00368	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.00192	0.00367	CcSEcCtD
Methylergometrine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.00191	0.00365	CcSEcCtD
Methylergometrine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.00191	0.00365	CcSEcCtD
Methylergometrine—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.0019	0.00364	CcSEcCtD
Methylergometrine—Nausea—Melphalan—peripheral nervous system neoplasm	0.00188	0.0036	CcSEcCtD
Methylergometrine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.00186	0.00356	CcSEcCtD
Methylergometrine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.00185	0.00355	CcSEcCtD
Methylergometrine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.00185	0.00355	CcSEcCtD
Methylergometrine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.00185	0.00354	CcSEcCtD
Methylergometrine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.00184	0.00351	CcSEcCtD
Methylergometrine—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.00182	0.00349	CcSEcCtD
Methylergometrine—HTR2A—cerebellum—peripheral nervous system neoplasm	0.0018	0.00431	CbGeAlD
Methylergometrine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.0018	0.00344	CcSEcCtD
Methylergometrine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.00178	0.0034	CcSEcCtD
Methylergometrine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.00171	0.00326	CcSEcCtD
Methylergometrine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.00169	0.00324	CcSEcCtD
Methylergometrine—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.00169	0.00323	CcSEcCtD
Methylergometrine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00167	0.00319	CcSEcCtD
Methylergometrine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00167	0.00319	CcSEcCtD
Methylergometrine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.00166	0.00317	CcSEcCtD
Methylergometrine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00161	0.00308	CcSEcCtD
Methylergometrine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00161	0.00307	CcSEcCtD
Methylergometrine—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.00159	0.00305	CcSEcCtD
Methylergometrine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00156	0.00298	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00155	0.00297	CcSEcCtD
Methylergometrine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.00155	0.00297	CcSEcCtD
Methylergometrine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00155	0.00296	CcSEcCtD
Methylergometrine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00154	0.00294	CcSEcCtD
Methylergometrine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.00153	0.00293	CcSEcCtD
Methylergometrine—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.00153	0.00292	CcSEcCtD
Methylergometrine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.00153	0.00292	CcSEcCtD
Methylergometrine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.0015	0.00287	CcSEcCtD
Methylergometrine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.00149	0.00285	CcSEcCtD
Methylergometrine—Rash—Vincristine—peripheral nervous system neoplasm	0.00148	0.00283	CcSEcCtD
Methylergometrine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00148	0.00283	CcSEcCtD
Methylergometrine—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.00147	0.00282	CcSEcCtD
Methylergometrine—Headache—Vincristine—peripheral nervous system neoplasm	0.00147	0.00281	CcSEcCtD
Methylergometrine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00145	0.00277	CcSEcCtD
Methylergometrine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00142	0.00271	CcSEcCtD
Methylergometrine—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.00141	0.0027	CcSEcCtD
Methylergometrine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.0014	0.00267	CcSEcCtD
Methylergometrine—Nausea—Vincristine—peripheral nervous system neoplasm	0.00139	0.00267	CcSEcCtD
Methylergometrine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.00139	0.00266	CcSEcCtD
Methylergometrine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00132	0.00252	CcSEcCtD
Methylergometrine—Rash—Cisplatin—peripheral nervous system neoplasm	0.00131	0.0025	CcSEcCtD
Methylergometrine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.00131	0.0025	CcSEcCtD
Methylergometrine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.0013	0.00249	CcSEcCtD
Methylergometrine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.00129	0.00247	CcSEcCtD
Methylergometrine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.00129	0.00246	CcSEcCtD
Methylergometrine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00126	0.0024	CcSEcCtD
Methylergometrine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.00125	0.0024	CcSEcCtD
Methylergometrine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.00123	0.00236	CcSEcCtD
Methylergometrine—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00121	0.00231	CcSEcCtD
Methylergometrine—Rash—Etoposide—peripheral nervous system neoplasm	0.0012	0.00229	CcSEcCtD
Methylergometrine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.0012	0.00229	CcSEcCtD
Methylergometrine—Headache—Etoposide—peripheral nervous system neoplasm	0.00119	0.00228	CcSEcCtD
Methylergometrine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.00116	0.00222	CcSEcCtD
Methylergometrine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.00115	0.00221	CcSEcCtD
Methylergometrine—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.00113	0.00216	CcSEcCtD
Methylergometrine—Nausea—Etoposide—peripheral nervous system neoplasm	0.00113	0.00216	CcSEcCtD
Methylergometrine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.00113	0.00216	CcSEcCtD
Methylergometrine—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.00111	0.00213	CcSEcCtD
Methylergometrine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.00107	0.00204	CcSEcCtD
Methylergometrine—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.00107	0.00204	CcSEcCtD
Methylergometrine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.00105	0.002	CcSEcCtD
Methylergometrine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.00104	0.002	CcSEcCtD
Methylergometrine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.00104	0.00199	CcSEcCtD
Methylergometrine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.00104	0.00199	CcSEcCtD
Methylergometrine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.00103	0.00197	CcSEcCtD
Methylergometrine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.00103	0.00197	CcSEcCtD
Methylergometrine—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000995	0.0019	CcSEcCtD
Methylergometrine—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000986	0.00189	CcSEcCtD
Methylergometrine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000967	0.00185	CcSEcCtD
Methylergometrine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000962	0.00184	CcSEcCtD
Methylergometrine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000957	0.00183	CcSEcCtD
Methylergometrine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000953	0.00182	CcSEcCtD
Methylergometrine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.00095	0.00182	CcSEcCtD
Methylergometrine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000921	0.00176	CcSEcCtD
Methylergometrine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000885	0.00169	CcSEcCtD
Methylergometrine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000879	0.00168	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000871	0.00167	CcSEcCtD
Methylergometrine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000842	0.00161	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000806	0.00154	CcSEcCtD
Methylergometrine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000779	0.00149	CcSEcCtD
Methylergometrine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000729	0.00139	CcSEcCtD
Methylergometrine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000704	0.00135	CcSEcCtD
Methylergometrine—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000677	0.0013	CcSEcCtD
Methylergometrine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000674	0.00129	CcSEcCtD
Methylergometrine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000672	0.00128	CcSEcCtD
Methylergometrine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000671	0.00128	CcSEcCtD
Methylergometrine—Headache—Epirubicin—peripheral nervous system neoplasm	0.000667	0.00128	CcSEcCtD
Methylergometrine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000652	0.00125	CcSEcCtD
Methylergometrine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000633	0.00121	CcSEcCtD
Methylergometrine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000627	0.0012	CcSEcCtD
Methylergometrine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000622	0.00119	CcSEcCtD
Methylergometrine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000621	0.00119	CcSEcCtD
Methylergometrine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000618	0.00118	CcSEcCtD
Methylergometrine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000586	0.00112	CcSEcCtD
Methylergometrine—HTR1F—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000329	0.00679	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000328	0.00677	CbGpPWpGaD
Methylergometrine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—peripheral nervous system neoplasm	0.000327	0.00675	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000315	0.0065	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000315	0.00649	CbGpPWpGaD
Methylergometrine—HTR1E—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000311	0.0064	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00031	0.00638	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000302	0.00622	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000297	0.00613	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000297	0.00612	CbGpPWpGaD
Methylergometrine—HTR2B—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000292	0.00603	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000286	0.0059	CbGpPWpGaD
Methylergometrine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.00028	0.00577	CbGpPWpGaD
Methylergometrine—DRD1—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000279	0.00575	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000277	0.00571	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000275	0.00566	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.00027	0.00557	CbGpPWpGaD
Methylergometrine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000266	0.00549	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000265	0.00546	CbGpPWpGaD
Methylergometrine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000262	0.00539	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000259	0.00534	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000254	0.00523	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000254	0.00523	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000251	0.00517	CbGpPWpGaD
Methylergometrine—DRD1—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000248	0.00511	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000239	0.00493	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000237	0.00488	CbGpPWpGaD
Methylergometrine—HTR2C—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000236	0.00486	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.00023	0.00474	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000225	0.00465	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.00022	0.00454	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000219	0.00452	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000217	0.00447	CbGpPWpGaD
Methylergometrine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000211	0.00435	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000207	0.00426	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000207	0.00426	CbGpPWpGaD
Methylergometrine—HTR2A—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.000205	0.00422	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000205	0.00422	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.0002	0.00413	CbGpPWpGaD
Methylergometrine—HTR2B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000194	0.00399	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000189	0.00389	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000185	0.00382	CbGpPWpGaD
Methylergometrine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000183	0.00378	CbGpPWpGaD
Methylergometrine—DRD1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000183	0.00376	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000175	0.00361	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000169	0.00349	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000168	0.00347	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000162	0.00334	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000161	0.00333	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00016	0.00329	CbGpPWpGaD
Methylergometrine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000159	0.00328	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000159	0.00327	CbGpPWpGaD
Methylergometrine—HTR2C—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000156	0.00322	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000153	0.00315	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000152	0.00314	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00015	0.00308	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000147	0.00304	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000142	0.00292	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000141	0.0029	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000139	0.00287	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000136	0.0028	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000136	0.0028	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000134	0.00276	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000133	0.00273	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00013	0.00269	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00013	0.00268	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000129	0.00266	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000129	0.00265	CbGpPWpGaD
Methylergometrine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000128	0.00264	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000128	0.00264	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000128	0.00263	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000124	0.00255	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000122	0.00251	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000121	0.0025	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000121	0.00249	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.00012	0.00248	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000119	0.00245	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000118	0.00244	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000118	0.00243	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000118	0.00243	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000117	0.00241	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000113	0.00234	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000113	0.00233	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000113	0.00232	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000112	0.0023	CbGpPWpGaD
Methylergometrine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.000111	0.0023	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000111	0.00229	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000106	0.00219	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000104	0.00214	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000103	0.00213	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000103	0.00213	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000103	0.00212	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NTS—peripheral nervous system neoplasm	9.95e-05	0.00205	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	9.85e-05	0.00203	CbGpPWpGaD
Methylergometrine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	9.56e-05	0.00197	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.54e-05	0.00197	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	9.5e-05	0.00196	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NTS—peripheral nervous system neoplasm	9.38e-05	0.00193	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	9.03e-05	0.00186	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CD55—peripheral nervous system neoplasm	9e-05	0.00185	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	8.94e-05	0.00184	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	8.89e-05	0.00183	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	8.38e-05	0.00173	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	8.33e-05	0.00172	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	8.25e-05	0.0017	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NTS—peripheral nervous system neoplasm	8.03e-05	0.00165	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	7.86e-05	0.00162	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.82e-05	0.00161	CbGpPWpGaD
Methylergometrine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	7.71e-05	0.00159	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.7e-05	0.00159	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.6e-05	0.00157	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.57e-05	0.00156	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.54e-05	0.00155	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.38e-05	0.00152	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	7.29e-05	0.0015	CbGpPWpGaD
Methylergometrine—DRD1—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	7.28e-05	0.0015	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.24e-05	0.00149	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.17e-05	0.00148	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.14e-05	0.00147	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.11e-05	0.00147	CbGpPWpGaD
Methylergometrine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	6.99e-05	0.00144	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.97e-05	0.00144	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.96e-05	0.00143	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	6.87e-05	0.00142	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.83e-05	0.00141	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.72e-05	0.00139	CbGpPWpGaD
Methylergometrine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	6.69e-05	0.00138	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	6.68e-05	0.00138	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.65e-05	0.00137	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.62e-05	0.00136	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.62e-05	0.00136	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	6.56e-05	0.00135	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.27e-05	0.00129	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.24e-05	0.00129	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	6.11e-05	0.00126	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VIP—peripheral nervous system neoplasm	6.08e-05	0.00125	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.88e-05	0.00121	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	5.84e-05	0.0012	CbGpPWpGaD
Methylergometrine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	5.64e-05	0.00116	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.61e-05	0.00116	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	5.34e-05	0.0011	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.3e-05	0.00109	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.28e-05	0.00109	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.23e-05	0.00108	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.11e-05	0.00105	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.93e-05	0.00102	CbGpPWpGaD
Methylergometrine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	4.9e-05	0.00101	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.88e-05	0.00101	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.7e-05	0.000969	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.64e-05	0.000956	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.62e-05	0.000952	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.6e-05	0.000948	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.47e-05	0.000922	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.47e-05	0.000921	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.43e-05	0.000914	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.36e-05	0.000898	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.34e-05	0.000894	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.26e-05	0.000878	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	4.22e-05	0.000869	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.22e-05	0.000869	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.02e-05	0.000828	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.91e-05	0.000806	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.71e-05	0.000765	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.69e-05	0.00076	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.66e-05	0.000755	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.65e-05	0.000753	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.61e-05	0.000744	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.44e-05	0.00071	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.44e-05	0.000709	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.44e-05	0.000709	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.34e-05	0.000689	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.31e-05	0.000683	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.24e-05	0.000669	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.23e-05	0.000666	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.22e-05	0.000664	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.15e-05	0.00065	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.15e-05	0.00065	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.13e-05	0.000646	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.13e-05	0.000644	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.1e-05	0.000639	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.04e-05	0.000626	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.98e-05	0.000615	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.98e-05	0.000615	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.86e-05	0.000591	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.78e-05	0.000573	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.77e-05	0.00057	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.74e-05	0.000565	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.72e-05	0.00056	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.62e-05	0.00054	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.61e-05	0.000538	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.59e-05	0.000533	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.56e-05	0.000528	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.44e-05	0.000503	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.23e-05	0.00046	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.19e-05	0.000452	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.15e-05	0.000443	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.12e-05	0.000438	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.03e-05	0.000419	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.02e-05	0.000417	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.02e-05	0.000417	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TP53—peripheral nervous system neoplasm	2e-05	0.000413	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.97e-05	0.000406	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.96e-05	0.000404	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.95e-05	0.000402	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.94e-05	0.000399	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.92e-05	0.000395	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.91e-05	0.000393	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.9e-05	0.000392	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.86e-05	0.000382	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.84e-05	0.000379	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.79e-05	0.00037	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.79e-05	0.000368	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.73e-05	0.000357	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.69e-05	0.000349	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.68e-05	0.000347	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.65e-05	0.000341	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.63e-05	0.000337	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.63e-05	0.000336	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.59e-05	0.000327	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.58e-05	0.000325	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.57e-05	0.000324	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.56e-05	0.000321	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.54e-05	0.000318	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.52e-05	0.000314	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.5e-05	0.00031	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.44e-05	0.000297	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.43e-05	0.000296	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.42e-05	0.000292	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.38e-05	0.000284	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.37e-05	0.000281	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.32e-05	0.000272	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.27e-05	0.000262	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.25e-05	0.000258	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.25e-05	0.000258	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.25e-05	0.000257	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.23e-05	0.000253	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.2e-05	0.000246	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.18e-05	0.000243	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.14e-05	0.000236	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.13e-05	0.000232	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.07e-05	0.00022	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.06e-05	0.000218	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.01e-05	0.000208	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	9.95e-06	0.000205	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	9.64e-06	0.000199	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	8.75e-06	0.00018	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	8.51e-06	0.000176	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.37e-06	0.000173	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.39e-06	0.000152	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	3.43e-06	7.06e-05	CbGpPWpGaD
